Literature DB >> 34793609

Setting up clinical trials for success: Applying preclinical advances in combined TGFβ/PD-L1 inhibition to ongoing clinical studies.

Alexander A Strait1, Xiao-Jing Wang1,2.   

Abstract

Combined TGFβ/PD-L1 inhibition is currently undergoing clinical trials in multiple cancer types. The early reported clinical trials of bintrafusp alfa, a bifunctional fusion protein targeting both of these pathways, have had mixed results. Here, we briefly review recent preclinical advances that can be used to refine these ongoing clinical trials and improve their outcomes.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  PD-L1 immune checkpoint blockade; TGFβ inhibition; clinical trials; immunotherapy; squamous cell carcinoma

Mesh：

Substances：

Year:  2021        PMID： 34793609      PMCID： PMC8799489          DOI： 10.1002/mc.23373

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN： 0899-1987            Impact factor:   4.784


  22 in total

1.  Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.

Authors:  Ezra E W Cohen; Denis Soulières; Christophe Le Tourneau; José Dinis; Lisa Licitra; Myung-Ju Ahn; Ainara Soria; Jean-Pascal Machiels; Nicolas Mach; Ranee Mehra; Barbara Burtness; Pingye Zhang; Jonathan Cheng; Ramona F Swaby; Kevin J Harrington
Journal:  Lancet       Date:  2018-11-30       Impact factor: 79.321

Review 2.  Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer.

Authors:  Stephen P Malkoski; Xiao-Jing Wang
Journal:  FEBS Lett       Date:  2012-02-03       Impact factor: 4.124

3.  Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.

Authors:  Koji Teramoto; Tomoyuki Igarashi; Yoko Kataoka; Mitsuaki Ishida; Jun Hanaoka; Hidetoshi Sumimoto; Yataro Daigo
Journal:  Lung Cancer       Date:  2019-09-16       Impact factor: 5.705

4.  Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis.

Authors:  Li Yang; Jianhua Huang; Xiubao Ren; Agnieszka E Gorska; Anna Chytil; Mary Aakre; David P Carbone; Lynn M Matrisian; Ann Richmond; P Charles Lin; Harold L Moses
Journal:  Cancer Cell       Date:  2008-01       Impact factor: 31.743

5.  Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation.

Authors:  Shi-Long Lu; Douglas Reh; Allen G Li; Jennifer Woods; Christopher L Corless; Molly Kulesz-Martin; Xiao-Jing Wang
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

6.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

7.  Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma.

Authors:  Alexander A Strait; Rachel A Woolaver; Spencer C Hall; Christian D Young; Sana D Karam; Antonio Jimeno; Yan Lan; David Raben; Jing H Wang; Xiao-Jing Wang
Journal:  Commun Biol       Date:  2021-08-25

8.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

9.  Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.

Authors:  Julius Strauss; Margaret E Gatti-Mays; Byoung Chul Cho; Andrew Hill; Sébastien Salas; Edward McClay; Jason M Redman; Houssein A Sater; Renee N Donahue; Caroline Jochems; Elizabeth Lamping; Andrea Burmeister; Jennifer L Marté; Lisa M Cordes; Marijo Bilusic; Fatima Karzai; Laureen S Ojalvo; Genevieve Jehl; P Alexander Rolfe; Christian S Hinrichs; Ravi A Madan; Jeffrey Schlom; James L Gulley
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751
View more
  1 in total

Review 1.  Duality of Interactions Between TGF-β and TNF-α During Tumor Formation.

Authors:  Zhi-Wei Liu; Yi-Ming Zhang; Li-Ying Zhang; Ting Zhou; Yang-Yang Li; Gu-Cheng Zhou; Zhi-Ming Miao; Ming Shang; Jin-Peng He; Nan- Ding; Yong-Qi Liu
Journal:  Front Immunol       Date:  2022-01-05       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.